Results of a nationwide survey on Japanese clinical practice in breast-conserving radiotherapy for breast cancer.
Journal
Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611
Informations de publication
Date de publication:
01 Jan 2019
01 Jan 2019
Historique:
received:
09
08
2018
pubmed:
27
11
2018
medline:
1
6
2019
entrez:
27
11
2018
Statut:
ppublish
Résumé
The Breast Cancer Group of the Japanese Radiation Oncology Study Group conducted a nationwide questionnaire survey on the clinical practice of postoperative radiotherapy for breast-conserving treatment for breast cancer. This questionnaire consisted of 18 questions pertaining to the annual number of treated patients, planning method, contouring structure, field design, dose-fractionated regimen, application of hypofractionated radiotherapy, boost irradiation, radiotherapy for synchronously bilateral breast cancer, and accelerated partial breast irradiation. The web-based questionnaire had responses from 293 Japanese hospitals. The results indicated the following: treatment planning is performed using relatively similar field designs and delivery methods; the field-in-field technique is used at more than one-third of institutes; the commonest criteria for boost irradiation is based on the surgical margin width (≤5 mm) and the second commonest criteria was age (≤40 or ≤50 years), although some facilities applied a different age criterion (>70 years) for omitting a tumor bed boost; for conventional fractionation, almost all institutes delivered 50 Gy in 25 fractions to the conserved whole breast and 10 Gy in 5 fractions to the tumor bed. This survey revealed that 43% of hospitals offered hypofractionated radiotherapy, and the most common regimens were 42.56 Gy in 16 fractions for whole-breast irradiation and 10.64 Gy in 4 fractions for boost irradiation. Almost all of the facilities irradiated both breasts simultaneously for synchronously bilateral breast cancer, and accelerated partial breast irradiation was rarely offered in Japan. This survey provided an overview of the current clinical practice of radiotherapy for breast-conserving treatment of breast cancer in Japan.
Identifiants
pubmed: 30476198
pii: 5195524
doi: 10.1093/jrr/rry095
pmc: PMC6373682
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-149Références
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Jpn J Clin Oncol. 2011 Nov;41(11):1241-3
pubmed: 21980050
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):51-7
pubmed: 23433799
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
J Clin Oncol. 2014 May 10;32(14):1507-15
pubmed: 24516019
JAMA. 2014 Dec 17;312(23):2542-50
pubmed: 25494006
Lancet Oncol. 2015 Jan;16(1):47-56
pubmed: 25500422
Breast Cancer (Dove Med Press). 2015 Oct 27;7:363-70
pubmed: 26604820
Breast Cancer. 2016 May;23(3):378-90
pubmed: 26883534
Radiat Oncol J. 2016 Jun;34(2):81-7
pubmed: 27306774
Cochrane Database Syst Rev. 2016 Jul 18;7:CD007077
pubmed: 27425375
Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79
pubmed: 27866865
J Clin Oncol. 2017 Feb 10;35(5):561-564
pubmed: 27937089
Lancet Oncol. 2017 Feb;18(2):259-268
pubmed: 28094198
Breast Cancer Res Treat. 2017 Apr;162(3):409-417
pubmed: 28160158
Lancet. 2017 Sep 9;390(10099):1048-1060
pubmed: 28779963
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Cochrane Database Syst Rev. 2017 Nov 06;11:CD011987
pubmed: 29105051
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124